Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer

Bochennek, Konrad; Allwinn, Regina; Langer, Rebecca C.; Becker, Martina; Keppler, Oliver T.; Klingebiel, Thomas; Lehrnbecher, Thomas

doi:10.1016/j.vaccine.2014.04.042

Cited by 60 publications

(63 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CNS complica- Up to 10% of people do not develop adequate protective antibodies (even after the recommended two doses of vaccine), in contrast to the longstanding immunity elicited by the natural infection. Vaccine-elicited immunity also likely wanes over time (63,64,66), and other factors can affect the response (65,67). Antiviral prophylaxis could protect unvaccinated individuals and prevent spread of virus in the population.…”

Section: Discussionmentioning

confidence: 99%

In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence

Figueira

Palermo

Veiga

et al. 2017

J Virol

View full text Add to dashboard Cite

Measles virus (MV) infection is undergoing resurgence and remains one of the leading causes of death among young children worldwide despite the availability of an effective measles vaccine. MV infects its target cells by coordinated action of the MV hemagglutinin (H) and fusion (F) envelope glycoproteins; upon receptor engagement by H, the prefusion F undergoes a structural transition, extending and inserting into the target cell membrane and then refolding into a postfusion structure that fuses the viral and cell membranes. By interfering with this structural transition of F, peptides derived from the heptad repeat (HR) regions of F can inhibit MV infection at the entry stage. In previous work, we have generated potent MV fusion inhibitors by dimerizing the F-derived peptides and conjugating them to cholesterol. We have shown that prophylactic intranasal administration of our lead fusion inhibitor efficiently protects from MV infection in vivo. We show here that peptides tagged with lipophilic moieties self-assemble into nanoparticles until they reach the target cells, where they are integrated into cell membranes. The selfassembly feature enhances biodistribution and the half-life of the peptides, while integration into the target cell membrane increases fusion inhibitor potency. These factors together modulate in vivo efficacy. The results suggest a new framework for developing effective fusion inhibitory peptides.IMPORTANCE Measles virus (MV) infection causes an acute illness that may be associated with infection of the central nervous system (CNS) and severe neurological disease. No specific treatment is available. We have shown that fusion-inhibitory peptides delivered intranasally provide effective prophylaxis against MV infection. We show here that specific biophysical properties regulate the in vivo efficacy of MV F-derived peptides.

show abstract

Section: Discussionmentioning

confidence: 99%

In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence

Figueira

Palermo

Veiga

et al. 2017

J Virol

View full text Add to dashboard Cite

show abstract

“…Besides prolonged immune impairment in transplant recipients, it has been shown that patients treated with chemotherapy for hematologic cancer may also lose pre-existing immunity. 308 It is obvious that the ongoing research in pathogen inactivation and pathogen removal is of great importance for blood recipients that are especially vulnerable to blood-transmitted infections (see Subsection 7.6; pathogen inactivation and removal). An important topic, especially relevant for blood disorders, is the question of whether blood and blood-derived products for immunosuppressed hematologic patients should be safer than for other categories of patients.…”

Section: Proposed Research For the Roadmapmentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

T he European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

show abstract

“…Regarding the level of evidence, three articles were classified as level I (15,(18)(19) , two as level II (17,20) and two as level III (16,21) . No studies located addressed the nursing diagnosis Ineffective protection among children and adolescents with cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Immune response after influenza vaccination in children with cancer (20) Insufficient antibody titers Side effects of treatment (chemotherapy), missed routine vaccinations Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer (21) Insufficient antibody titers Side effects of treatment (chemotherapy), missed routine vaccinations Cellular and Molecular Immunology (12) ; Kuby Immunology (13) ; The Immune System (14) . …”

Section: Clinical Indicators Etiological Factorsmentioning

confidence: 99%

“…Another study that analyzed the loss of protective immunity (immunity at diagnosis and immunity after treatment completion) against preventable diseases in children treated for malignant disease has shown that a significant number of these lose humoral immunity against measles, mumps, rubella and varicella after chemotherapy (21) . This contextualizes the clinical indicator insufficient antibody titer, demonstrating that the protection afforded by vaccines may be affected following the application of antineoplastic therapy, thereby exposing children and adolescents to diseases that should not occur after immunization.…”

Section: In Relation To the Clinical Indicators Of Protection In The mentioning

confidence: 99%

See 1 more Smart Citation

Clinical indicators for nursing diagnosis Ineffective protection in adolescents with cancer

et al. 2017

View full text Add to dashboard Cite

Objective: To investigate scientific evidence related to the term protection and clinical indicators and etiologic factors for nursing diagnosis Ineffective protection in adolescents with cancer. Method: Integrative literature review in the databases of Scopus, Web of Science, National Library of Medicine and National Institutes of Health (PubMed) and Cochrane; by intersection of the descriptors protection and childhood cancer, which resulted in seven articles. These were insufficient for a comprehension of the term protection and aspects related to its impairment, therefore it was necessary to include a further three reference books. Results: Five clinical indicators and three etiologic factors associated to Ineffective protection were identified some of which were not cited in NANDA-International. Conclusions: There are clinical and etiologic factors important for the identification of ineffective protection in adolescents with cancer. Descriptors: Nursing Diagnosis; Protection; Immunological System; Cancer; Adolescent. RESUMO Objetivo: Investigar as evidências científicas acerca do termo proteção e dos indicadores clínicos e fatores etiológicos do diagnóstico de enfermagem Proteção ineficaz em adolescentes com câncer. Método: Realizou-se uma revisão integrativa nas bases de dados Scopus, Web of Science, National Library of Medicine and National Institutes of Health (PubMed) e Cochrane; por meio do cruzamento dos termos protection and childhood cancer, que resultou em sete artigos. Estes não foram suficientes para a compreensão do termo proteção e dos aspectos associados à sua alteração, sendo necessário incluir três livros. Resultados: Foram identificados cinco indicadores clínicos e três fatores etiológicos associados a uma proteção ineficaz, alguns não citados na NANDA-Internacional. Conclusões: Existem indicadores clínicos e fatores etiológicos que podem ser importantes para identificar uma alteração na proteção de adolescentes com câncer. Descritores: Diagnóstico de Enfermagem; Proteção; Sistema Imunológico; Neoplasias; Adolescente. RESUMEN Objetivo: Investigar las evidencias científicas acerca del término protección y de los indicadores clínicos y factores etiológicos del diagnóstico de enfermería Protección ineficaz en adolescentes con cáncer. Método: Se realizó una revisión integradora en las bases de datos Scopus,Web of Science, National Library of Medicine andNationalInstitutesof Health (PubMed) y Cochrane; por medio del cruce de los términos protection and childhood cancer, que resultó en siete artículos. Estos no fueron suficientes para la comprensión del término protección y de los aspectos asociados a su alteración, siendo necesario incluir tres libros. Resultados: Fueron identificados cinco indicadores clínicos y tres factores etiológicos asociados a una protección ineficaz, algunos no citados en la NANDA-Internacional. Conclusión: Existen indicadores clínicos y factores etiológicos que pueden ser importantes para identificar una alteración en la protección de adolescentes con cáncer.

show abstract

Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer

Cited by 60 publications

References 27 publications

In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence

In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence

The European Hematology Association Roadmap for European Hematology Research: a consensus document

Clinical indicators for nursing diagnosis Ineffective protection in adolescents with cancer

Contact Info

Product

Resources

About